Group 1 - The company, China COSCO Shipping Ports (01199.HK), will hold a board meeting on March 18, 2026, at its headquarters in Hong Kong to approve the annual results for the year ending December 31, 2025, and consider the distribution of dividends [1]

Group 1 - The core point of the article is that Lianhua Supermarket (00980.HK) announced a net loss of approximately RMB 359 million attributable to shareholders for the fiscal year ending December 31, 2024, but expects a significant reduction in net loss for the fiscal year ending December 31, 2025, with a decrease of about 35% to 55% [1] Group 2 - The company anticipates a notable improvement in its financial performance in the upcoming fiscal year, indicating a positive outlook for recovery [1]

Group 1 - The board of Bohai Bank (09668.HK) has approved the appointment of Qu Hongzhi as the Chief Compliance Officer, effective from March 4, 2026, until the end of his term as President [1]

涂先生已确认与本行董事会和高管层没有任何意见分歧，同时也没有任何与辞任有关而需要通知本行股 东和债权人的事项。 格隆汇3月4日丨交通银行(601328.SH)公布，涂宏先生因到退休年龄，今日已向本行董事会提交书面报 告，辞去本行业务总监（同业与市场业务）职务，辞任自2026年3月4日起生效。 ...

Core Viewpoint - China Tower (00788.HK) announced a board meeting scheduled for March 18, 2026, to approve the financial performance for the year ending December 31, 2025, and to consider the distribution of a final dividend, if any [1] Financial Performance - The board meeting will focus on approving the financial results for the fiscal year ending December 31, 2025 [1] Dividend Consideration - The meeting will also consider the potential distribution of a final dividend for the fiscal year [1]

Group 1 - The core point of the article is that Geely Automobile announced a share buyback plan, spending HKD 112 million to repurchase 7.378 million shares at a price range of HKD 14.97 to 15.41 per share [1] Group 2 - The buyback is scheduled for March 4, 2026, indicating the company's strategy to enhance shareholder value [1] - The repurchase price reflects a commitment to support the stock price amid market fluctuations [1] - This move may signal confidence in the company's future performance and financial health [1]

格隆汇3月4日丨山东新华制药股份(00719.HK)公布，近日，公司全资子公司山东淄博新达制药有限公司 (以下简称"新达制药")收到国家药品监督管理局核准签发的沙格列汀二甲双胍缓释片(Ⅰ)、(Ⅲ)(以下简 称"本品")《药品注册证书》。 药品名称：沙格列汀二甲双胍缓释片(Ⅰ)、(Ⅲ) 剂型：片剂 规格：沙格列汀二甲双胍缓释片(Ⅰ)：每片含沙格列汀5mg和盐酸二甲双胍1000mg。沙格列汀二甲双胍 缓释片(Ⅲ)：每片含沙格列汀2.5mg和盐酸二甲双胍1000mg。药品分类：处方药 注册分类：化学药品4类 申请事项：药品注册(境内生产) 受理号：CYHS2401958、CYHS2401959 药品批准文号：国药准字H20263398、国药准字H20263445 证书编号：2026S00469、2026S00534 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注册的有关要求， 批准注册，发给药品注册证书。质量标准、说明书、标签及生产工艺照所附执行。药品生产企业应当符 合药品生产质量管理规范要求方可生产销售。 申请人：山东淄博新达制药有限公司 ...

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration certificate of Entacapone tablets, which can be used as an adjunct therapy for Parkinson's disease when standard medications are insufficient [1] Company Summary - The approved product, Entacapone tablets, is indicated for use alongside standard medications such as Levodopa/Benserazide or Levodopa/Carbidopa [1] - The indication for Entacapone includes treatment for Parkinson's disease and symptom fluctuations that are not controlled by existing therapies [1]

格隆汇3月4日丨山东新华制药股份(00719.HK)公布，近日，公司全资子公司山东淄博新达制药有限公司 (以下简称"新达制药")收到国家药品监督管理局核准签发的沙格列汀二甲双胍缓释片(Ⅰ)、(Ⅲ)(以下简 称"本品")《药品注册证书》。 药品名称：沙格列汀二甲双胍缓释片(Ⅰ)、(Ⅲ) 剂型：片剂 规格：沙格列汀二甲双胍缓释片(Ⅰ)：每片含沙格列汀5mg和盐酸二甲双胍1000mg。沙格列汀二甲双胍 缓释片(Ⅲ)：每片含沙格列汀2.5mg和盐酸二甲双胍1000mg。药品分类：处方药 注册分类：化学药品4类 申请人：山东淄博新达制药有限公司 申请事项：药品注册(境内生产) 受理号：CYHS2401958、CYHS2401959 药品批准文号：国药准字H20263398、国药准字H20263445 证书编号：2026S00469、2026S00534 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注册的有关要求， 批准注册，发给药品注册证书。质量标准、说明书、标签及生产工艺照所附执行。药品生产企业应当符 合药品生产质量管理规范要求方可生产销售。 ...

Core Viewpoint - Goldman Sachs reported that ASMPT's revenue in Q4 last year increased by 18% quarter-on-quarter, exceeding management guidance and market expectations [1] Financial Performance - Gross margin was 36.5%, lower than Goldman Sachs' expectation of 38.8% but higher than market expectations of 35.7% [1] - Net profit for the period reached HKD 957 million, significantly above Goldman Sachs' forecast of HKD 360 million and market expectations of HKD 172 million, primarily driven by gains from the sale of Advanced Packaging Materials International (AAMI) [1] Future Guidance - ASMPT's revenue guidance for Q1 this year is between USD 470 million and USD 530 million, representing a year-on-year growth of 17% to 32%, and a quarter-on-quarter decline of 8% to a growth of 4% [1] - The median of the guidance is slightly above Goldman Sachs' and market expectations [1] Rating and Target Price - Goldman Sachs maintains a "Neutral" rating for ASMPT with a target price of HKD 90.7 [1]